• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

何时是筛查和评估可治疗遗传疾病的最佳时机?:从寿命角度看。

When is the best time to screen and evaluate for treatable genetic disorders?: A lifespan perspective.

机构信息

Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA.

Wadsworth Center, New York State Department of Health, Division of Genetics, Albany, New York, USA.

出版信息

Am J Med Genet C Semin Med Genet. 2023 Mar;193(1):44-55. doi: 10.1002/ajmg.c.32036. Epub 2023 Mar 6.

DOI:10.1002/ajmg.c.32036
PMID:36876995
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10475244/
Abstract

This paper focuses on the question of, "When is the best time to identify an individual at risk for a treatable genetic condition?" In this review, we describe a framework for considering the optimal timing for pursuing genetic and genomic screening for treatable genetic conditions incorporating a lifespan approach. Utilizing the concept of a carousel that represents the four broad time periods when critical decisions might be made around genetic diagnoses during a person's lifetime, we describe genetic testing during the prenatal period, the newborn period, childhood, and adulthood. For each of these periods, we describe the objectives of genetic testing, the current status of screening or testing, the near-term vision for the future of genomic testing, the advantages and disadvantages of each approach, and the feasibility and ethical considerations of testing and treating. The notion of a "Genomics Passbook" is one where an early genomic screening evaluation could be performed on each individual through a public health program, with that data ultimately serving as a "living document" that could be queried and/or reanalyzed at prescribed times during the lifetime of that person, or in response to concerns about symptoms of a genetic disorder in that individual.

摘要

本文聚焦于“何时是识别有治疗性遗传疾病风险个体的最佳时机?”这一问题。在这篇综述中,我们描述了一个考虑最佳时机进行可治疗遗传疾病基因和基因组筛查的框架,该框架采用了一种寿命方法。我们利用代表个体一生中可能做出与遗传诊断相关的关键决策的四个广泛时间段的旋转木马概念,描述了产前、新生儿期、儿童期和成年期的基因检测。对于每个阶段,我们描述了基因检测的目标、当前的筛查或检测状况、基因组检测未来的近期愿景、每种方法的优缺点,以及检测和治疗的可行性和伦理考虑。“基因组存折”的概念是,通过公共卫生计划对每个人进行早期基因组筛查评估,这些数据最终将成为一份“活文档”,可以在那个人的一生中规定的时间查询和/或重新分析,或者在出现该个体遗传疾病症状的担忧时进行查询和/或重新分析。

相似文献

1
When is the best time to screen and evaluate for treatable genetic disorders?: A lifespan perspective.何时是筛查和评估可治疗遗传疾病的最佳时机?:从寿命角度看。
Am J Med Genet C Semin Med Genet. 2023 Mar;193(1):44-55. doi: 10.1002/ajmg.c.32036. Epub 2023 Mar 6.
2
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
3
[Genomic newborn screening. Perspective from the Ethics Commission of the Spanish Society for Human Genetics. Part II: Ethical, legal and social issues (ELSIs) of the introduction of next generation sequencing technologies in a public health newborn screening program.].[基因组新生儿筛查。西班牙人类遗传学会伦理委员会的观点。第二部分:在公共卫生新生儿筛查项目中引入下一代测序技术的伦理、法律和社会问题(ELSI)。]
Rev Esp Salud Publica. 2022 Mar 14;96:e202203030.
4
Promises and challenges of genomic newborn screening (NBS) - lessons from public health NBS programs.基因组新生儿筛查(NBS)的前景与挑战——来自公共卫生NBS项目的经验教训
Pediatr Res. 2024 Nov 8. doi: 10.1038/s41390-024-03689-0.
5
Pilot Medical Certification飞行员医学认证
6
'Integrating Ethics and Equity with Economics and Effectiveness for newborn screening in the genomic age: A qualitative study protocol of stakeholder perspectives.在基因组时代进行新生儿筛查时,将伦理学、公平性与经济学和有效性相结合:利益相关者观点的定性研究方案。
PLoS One. 2024 Mar 25;19(3):e0299336. doi: 10.1371/journal.pone.0299336. eCollection 2024.
7
Neonatal screening for treatable and untreatable disorders: prospective parents' opinions.新生儿可治疗和不可治疗疾病的筛查:准父母的意见。
Pediatrics. 2010 Jan;125(1):e99-106. doi: 10.1542/peds.2009-0269. Epub 2009 Dec 21.
8
Evaluating parents' decisions about next-generation sequencing for their child in the NC NEXUS (North Carolina Newborn Exome Sequencing for Universal Screening) study: a randomized controlled trial protocol.在北卡罗来纳州新生儿外显子测序通用筛查(NC NEXUS)研究中评估父母为其子女进行下一代测序的决策:一项随机对照试验方案。
Trials. 2018 Jun 28;19(1):344. doi: 10.1186/s13063-018-2686-4.
9
Genomic sequencing in newborn screening: balancing consent with the right of the asymptomatic at-risk child to be found.新生儿筛查中的基因组测序:平衡知情同意与发现无症状高危儿童的权利。
Eur J Hum Genet. 2025 Mar;33(2):182-188. doi: 10.1038/s41431-024-01677-w. Epub 2024 Aug 12.
10
Expanding the newborn screen: terrific or troubling?扩大新生儿筛查范围:是了不起还是令人担忧?
MCN Am J Matern Child Nurs. 1998 Sep-Oct;23(5):266-71. doi: 10.1097/00005721-199809000-00010.

引用本文的文献

1
Integrating Genetic Insights, Technological Advancements, Screening, and Personalized Pharmacological Interventions in Childhood Obesity.整合儿童肥胖症的遗传见解、技术进步、筛查和个性化药物干预措施
Adv Ther. 2025 Jan;42(1):72-93. doi: 10.1007/s12325-024-03057-8. Epub 2024 Nov 13.
2
Current Status of Newborn Bloodspot Screening Worldwide 2024: A Comprehensive Review of Recent Activities (2020-2023).《2024年全球新生儿血斑筛查现状:2020 - 2023年近期活动综合回顾》
Int J Neonatal Screen. 2024 May 23;10(2):38. doi: 10.3390/ijns10020038.
3
Genomic sequencing for newborn screening: current perspectives and challenges.新生儿筛查的基因组测序:当前观点与挑战
Croat Med J. 2024 Jun 13;65(3):261-267. doi: 10.3325/cmj.2024.65.261.
4
Eliciting parental preferences and values for the return of additional findings from genomic sequencing.引出父母对于基因组测序额外结果反馈的偏好和价值观。
NPJ Genom Med. 2024 Feb 14;9(1):10. doi: 10.1038/s41525-024-00399-8.
5
Australian Public Perspectives on Genomic Newborn Screening: Risks, Benefits, and Preferences for Implementation.澳大利亚公众对新生儿基因组筛查的看法:实施的风险、益处及偏好
Int J Neonatal Screen. 2024 Jan 17;10(1):6. doi: 10.3390/ijns10010006.
6
The Rare Diseases Clinical Research Network: a model for clinical trial readiness.罕见病临床研究网络:临床试验准备就绪的典范。
Ther Adv Rare Dis. 2023 Dec 26;4:26330040231219272. doi: 10.1177/26330040231219272. eCollection 2023 Jan-Dec.
7
The Long-term Lung and Respiratory Outcomes of Acid Sphingomyelinase Deficiency: A 10- and 20-year Follow-up Study.酸性鞘磷脂酶缺乏症的长期肺部和呼吸系统结局:10 年和 20 年随访研究。
In Vivo. 2024 Jan-Feb;38(1):437-444. doi: 10.21873/invivo.13457.
8
Genomic newborn screening for rare diseases.针对罕见病的基因组新生儿筛查。
Nat Rev Genet. 2023 Nov;24(11):755-766. doi: 10.1038/s41576-023-00621-w. Epub 2023 Jun 29.

本文引用的文献

1
Modelling the Cost-Effectiveness and Budget Impact of a Newborn Screening Program for Spinal Muscular Atrophy and Severe Combined Immunodeficiency.脊髓性肌萎缩症和重症联合免疫缺陷新生儿筛查项目的成本效益及预算影响建模
Int J Neonatal Screen. 2022 Jul 20;8(3):45. doi: 10.3390/ijns8030045.
2
ACMG SF v3.1 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG).美国医学遗传学与基因组学学会(ACMG)关于临床外显子组和基因组测序中次要发现报告的ACMG SF v3.1清单:一项政策声明
Genet Med. 2022 Jul;24(7):1407-1414. doi: 10.1016/j.gim.2022.04.006. Epub 2022 Jun 17.
3
The Impact of Proband Indication for Genetic Testing on the Uptake of Cascade Testing Among Relatives.先证者基因检测指征对亲属级联检测接受度的影响。
Front Genet. 2022 Jun 16;13:867226. doi: 10.3389/fgene.2022.867226. eCollection 2022.
4
Financial cost and quality of life of patients with spinal muscular atrophy identified by symptoms or newborn screening.症状或新生儿筛查发现的脊髓性肌萎缩症患者的经济成本和生活质量。
Dev Med Child Neurol. 2023 Jan;65(1):67-77. doi: 10.1111/dmcn.15286. Epub 2022 Jun 8.
5
Education and Consent for Population-Based DNA Screening: A Mixed-Methods Evaluation of the Early Check Newborn Screening Pilot Study.基于人群的DNA筛查的教育与知情同意:早期检查新生儿筛查试点研究的混合方法评估
Front Genet. 2022 May 12;13:891592. doi: 10.3389/fgene.2022.891592. eCollection 2022.
6
Analysis of the 2000 to 2018 autism and developmental disabilities monitoring network surveillance reports: Implications for primary care clinicians.2000 至 2018 年自闭症与发育障碍监测网络监测报告分析:对基层医疗临床医生的启示。
J Pediatr Nurs. 2022 Jul-Aug;65:55-68. doi: 10.1016/j.pedn.2022.04.014. Epub 2022 May 5.
7
A Window of Opportunity for Newborn Screening.新生儿筛查的机会之窗。
Mol Diagn Ther. 2022 May;26(3):253-261. doi: 10.1007/s40291-022-00590-6. Epub 2022 May 4.
8
Expert Evaluation of Strategies to Modernize Newborn Screening in the United States.美国新生儿筛查现代化策略的专家评估。
JAMA Netw Open. 2021 Dec 1;4(12):e2140998. doi: 10.1001/jamanetworkopen.2021.40998.
9
Returning actionable genomic results in a research biobank: Analytic validity, clinical implementation, and resource utilization.研究生物库中可操作基因组结果的返还:分析有效性、临床实施和资源利用。
Am J Hum Genet. 2021 Dec 2;108(12):2224-2237. doi: 10.1016/j.ajhg.2021.10.005. Epub 2021 Nov 8.
10
Undiagnosed Phenylketonuria Can Exist Everywhere: Results From an International Survey.未诊断的苯丙酮尿症可能无处不在:一项国际调查结果。
J Pediatr. 2021 Dec;239:231-234.e2. doi: 10.1016/j.jpeds.2021.08.070. Epub 2021 Aug 30.